Partnerships

Strategic Collaborations

Cancer research, development, commercialization, manufacturing, and distribution are complex challenges that require a coordinated, collaborative approach. To address these challenges, Cellectar partners with select companies, healthcare thought leaders, universities, government agencies, clinical experts, and patient advocates. These strategic collaborations strengthen our ability to advance precision oncology, expand access to critical therapies, and accelerate the delivery of meaningful treatments to patients with advanced cancers.

Our Focus

Iterative Screening Drug Discovery Paradigm

The modular nature of our platform allows us iteratively design molecules and more efficiently discover new treatment options for cancer patients. This approach enables us to rapidly and systematically screen multiple series’ of PDCs to produce optimal product

Strategic Drug Development

We are advancing product candidates for diseases possessing clear unmet need. Our development efforts focus on product candidates with the potential for accelerated regulatory approval and commercialization. This approach allows for rapid and streamlined clinical development for diseases with limited treatment options.

Collaborations Support Innovation & Growth

Collaboration(s) may supplement internal resources, provide access to novel molecules for the development of PDCs, and broaden our product pipeline. We expect that some of these collaborations may generate near-term capital supporting company operations, and product development.

Partnered Organizations